David H. Gutmann

Q: What Schools Are Affiliated With David H. Gutmann

David H. Gutmann is affiliated with the following schools: Washington University in St. Louis, University of Michigan, Stanford University, Johns Hopkins University, University of California, San Francisco, King's College London, University of Pennsylvania

David H. Gutmann's AcademicInfluence.com Rankings

David H. Gutmann

Medical

#982

World Rank

#1265

Historical Rank

#323

USA Rank

Neurology

#97

World Rank

#147

Historical Rank

#32

USA Rank

medical Degrees

Download Badge

Medical

David H. Gutmann's Degrees

Doctorate Neurology Stanford University
PhD Neuroscience University of California, San Francisco

Why Is David H. Gutmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Hillel Gutmann is an American neurologist-neuroscientist. He teaches at Washington University in St. Louis, where he is the Donald O. Schnuck Family Professor, and Director of the Washington University Neurofibromatosis Center. He is an international expert in Neurofibromatosis, pioneering the use of preclinical models to understand brain tumors and neurodevelopmental delays in children with NF1.

(See a Problem?)

David H. Gutmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. (1997) (1193)
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis (2008) (1030)
The role of microglia and macrophages in glioma maintenance and progression (2015) (973)
Neurofibromatosis type 1 (2017) (685)
The question of familial meningiomas and schwannomas: (2000) (633)
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. (2002) (632)
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients (1992) (621)
Subtypes of medulloblastoma have distinct developmental origins (2010) (581)
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex (2008) (578)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
Neurofibromatosis Type 1 Revisited (2009) (566)
Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations (2007) (497)
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. (2001) (441)
Challenges to curing primary brain tumours (2019) (414)
Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning (2008) (391)
cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. (1991) (388)
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. (2017) (359)
Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force (2002) (356)
Neurofibromatosis type 1: a multidisciplinary approach to care (2014) (353)
Astrocyte‐specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures (2002) (349)
Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the nf1 optic pathway glioma task force (1997) (314)
Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation (2002) (293)
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. (2001) (283)
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. (2005) (281)
Identification of the neurofibromatosis type 1 gene product. (1991) (272)
Molecular pathogenesis of meningiomas (2004) (257)
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. (2003) (257)
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. (2010) (252)
Malignant peripheral nerve sheath tumors in neurofibromatosis 1. (2000) (247)
Differential Effects of cAMP in Neurons and Astrocytes (1999) (235)
Interdomain binding mediates tumor growth suppression by the NF2 gene product (1997) (231)
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. (2012) (230)
Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo (2004) (219)
Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation (2002) (205)
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. (2005) (204)
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. (2006) (201)
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. (2002) (194)
Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. (2011) (191)
Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. (2007) (190)
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation (2005) (183)
Aggressive Phenotypic and Genotypic Features in Pediatric and NF2‐Associated Meningiomas: A Clinicopathologic Study of 53 Cases (2001) (183)
Merlin differentially associates with the microtubule and actin cytoskeleton (1998) (183)
Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model (2003) (180)
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. (2007) (179)
Nectin-like proteins mediate axon–Schwann cell interactions along the internode and are essential for myelination (2007) (178)
Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. (2000) (172)
A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity (1993) (169)
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. (2007) (167)
Intracranial gliomas in neurofibromatosis type 1. (1999) (167)
Merlin, DAL‐1, and Progesterone Receptor Expression in Clinicopathologic Subsets of Meningioma: A Correlative Immunohistochemical Study of 175 Cases (2000) (166)
Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. (2011) (163)
Plexiform neurofibromas in NF1: toward biologic-based therapy. (2002) (163)
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. (1997) (161)
Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients (2008) (160)
Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas (1997) (160)
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. (2008) (157)
The neurofibromatosis type 1 gene and its protein product, neurofibromin (1993) (156)
Loss of Neurofibromin Is Associated with Activation of RAS/MAPK and PI3‐K/AKT Signaling in a Neurofibromatosis 1 Astrocytoma (2000) (152)
Oligodendroglial myelination requires astrocyte-derived lipids (2017) (152)
Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. (2003) (151)
Neurofibromatosis type 1 (NF1): diagnosis and management. (2013) (150)
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation (2021) (148)
O-20-295 RAS-GTP levels are elevated in human NF1 peripheral nerve tumors (1996) (147)
The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes (2003) (147)
Loss of neurofibromatosis 1 (NF1) gene expression in NF1‐associated pilocytic astrocytomas (2000) (144)
Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology (2019) (144)
Recent advances in neurofibromatosis type 1 (2004) (143)
Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L (2004) (142)
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines (1993) (141)
Optic pathway gliomas in neurofibromatosis type 1: The effect of presenting symptoms on outcome (2003) (141)
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules (1993) (137)
Roadmap for the Emerging Field of Cancer Neuroscience (2020) (136)
Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression (2004) (135)
Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). (2002) (133)
Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. (2000) (131)
Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation (1999) (131)
BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma (2013) (129)
Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. (2010) (129)
Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. (1999) (127)
Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)‐regulated glial proliferation (2009) (126)
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. (2008) (125)
Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis (2011) (123)
Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. (2000) (122)
Astrocyte-Derived Vascular Endothelial Growth Factor Stabilizes Vessels in the Developing Retinal Vasculature (2010) (122)
Epileptogenesis and Reduced Inward Rectifier Potassium Current in Tuberous Sclerosis Complex‐1–Deficient Astrocytes (2005) (122)
DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo (2004) (121)
Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex (2007) (121)
Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes (2011) (120)
Expression of ICAM-1, TNF-α, NFκB, and MAP kinase in tubers of the tuberous sclerosis complex (2003) (120)
Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas (2015) (119)
Differential NF1, p16, and EGFR Patterns by Interphase Cytogenetics (FISH) in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Morphologically Similar Spindle Cell Neoplasms (2002) (119)
Neurofibromin Regulates Neural Stem Cell Proliferation, Survival, and Astroglial Differentiation In Vitro and In Vivo (2005) (119)
Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K* (2003) (118)
NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. (2001) (117)
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1 (2014) (117)
Immunohistochemical Analysis Supports a Role for INI1/SMARCB1 in Hereditary Forms of Schwannomas, but Not in Solitary, Sporadic Schwannomas (2008) (115)
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. (2005) (113)
Neurofibromatosis 1: from lab bench to clinic. (2005) (113)
The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Gα12/13 and RhoA (2014) (112)
Late-onset optic pathway tumors in children with neurofibromatosis 1 (2004) (111)
High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. (2006) (111)
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. (2007) (110)
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas (2008) (107)
The neurofibromatoses: when less is more. (2001) (107)
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. (2015) (107)
Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma (2019) (106)
Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. (2002) (106)
Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. (2010) (106)
Neurofibromatosis-1 Heterozygosity Increases Microglia in a Spatially and Temporally Restricted Pattern Relevant to Mouse Optic Glioma Formation and Growth (2011) (106)
Optic Pathway Gliomas in Neurofibromatosis Type 1 (2018) (105)
Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. (2008) (102)
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma (2009) (102)
Defective cAMP Generation Underlies the Sensitivity of CNS Neurons to Neurofibromatosis-1 Heterozygosity (2010) (101)
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. (2012) (100)
Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function (2004) (99)
Merlin is a potent inhibitor of glioma growth. (2008) (99)
Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. (2010) (99)
Defects in neurofibromatosis 2 protein function can arise at multiple levels. (1998) (99)
Microglia states and nomenclature: A field at its crossroads (2022) (99)
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back (2010) (94)
Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. (2006) (94)
Neurofibromatosis 1: closing the GAP between mice and men. (2003) (93)
Deconvoluting mTOR biology (2012) (92)
Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. (1995) (92)
Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle (1995) (92)
Astrocyte gp130-expression is critical for the control of Toxoplasma encephalitis (2008) (91)
Neurofibromatosis type 1 — a model for nervous system tumour formation? (2005) (90)
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation (2007) (90)
Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor (2011) (89)
Functional outcome measures for NF1-associated optic pathway glioma clinical trials (2013) (89)
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma (2008) (89)
Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). (2016) (88)
Neurofibromatosis 1 (NF1) heterozygosity results in a cell‐autonomous growth advantage for astrocytes (2001) (87)
BRAF-V600E mutation in pediatric and adult glioblastoma. (2014) (87)
Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. (2012) (86)
Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. (2002) (86)
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma (2013) (86)
Tsc 2 gene inactivation causes a more severe epilepsy phenotype than Tsc 1 inactivation in a mouse model of Tuberous Sclerosis Complex (2011) (86)
Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. (2009) (86)
Gene Expression Profiling Reveals Unique Molecular Subtypes of Neurofibromatosis Type I‐associated and Sporadic Malignant Peripheral Nerve Sheath Tumors (2004) (84)
T-Cadherin-Mediated Cell Growth Regulation Involves G2 Phase Arrest and Requires p21CIP1/WAF1 Expression (2003) (84)
Meningioma: an update (2004) (84)
Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner (2011) (83)
Ezrin, radixin, and moesin are components of Schwann cell microvilli (2001) (82)
Reduced microglial CX3CR1 expression delays neurofibromatosis‐1 glioma formation (2013) (82)
Modeling cognitive dysfunction in neurofibromatosis-1 (2013) (81)
Neurofibromatosis Type 1: Modeling CNS Dysfunction (2012) (81)
Optimizing biologically targeted clinical trials for neurofibromatosis (2013) (80)
Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells (1996) (80)
Promoter hypermethylation of the potential tumor suppressor DAL‐1/4.1B gene in renal clear cell carcinoma (2006) (80)
Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/− cells (2002) (80)
Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I (1994) (80)
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma (2005) (80)
Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells (2005) (79)
Tumorigenesis in neurofibromatosis: new insights and potential therapies. (2001) (79)
Epilepsy in individuals with neurofibromatosis type 1 (2013) (79)
The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. (2000) (79)
Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation (2004) (78)
The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner (2008) (77)
Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis (2003) (75)
Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1 (2003) (75)
RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth1 (2015) (73)
The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. (2010) (73)
Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II study (2014) (72)
Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord (2012) (72)
Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. (2017) (72)
Loss of Tumor Suppressor in Lung Cancer‐1 (TSLC1) Expression in Meningioma Correlates with Increased Malignancy Grade and Reduced Patient Survival (2004) (72)
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1 (2016) (71)
Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future (2017) (71)
Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. (2015) (71)
Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. (2015) (70)
Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues (1995) (70)
High‐fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism (2012) (70)
Microglia as Dynamic Cellular Mediators of Brain Function. (2019) (70)
Mammalian target of rapamycin: master regulator of cell growth in the nervous system. (2007) (69)
Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations (1999) (69)
Dopamine deficiency underlies learning deficits in neurofibromatosis‐1 mice (2013) (69)
Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. (2002) (69)
Attention Skills in Children With Neurofibromatosis Type 1 (2013) (68)
Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. (2014) (67)
Tumorigenesis in the brain: location, location, location. (2007) (67)
Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules (1997) (66)
Astrocyte gp130 Expression Is Critical for the Control of Toxoplasma Encephalitis1 (2008) (66)
The Protein 4.1 Tumor Suppressor, DAL-1, Impairs Cell Motility, But Regulates Proliferation in a Cell-Type-Specific Fashion (2001) (66)
Developmental regulation of a neuron‐specific neurofibromatosis 1 isoform (1999) (64)
Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. (2007) (64)
Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes (2010) (64)
Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research (2012) (63)
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. (2005) (63)
The molecular and cell biology of pediatric low-grade gliomas (2014) (62)
Histopathologic predictors of pilocytic astrocytoma event-free survival (2009) (62)
Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. (2012) (62)
Mouse models of neurofibromatosis 1 and 2. (2002) (62)
Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues (2000) (62)
Neurofibromatosis type 1. (2015) (62)
Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. (2003) (61)
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas (2001) (59)
The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1 (2006) (59)
Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. (2001) (59)
MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) (59)
Harnessing preclinical mouse models to inform human clinical cancer trials. (2006) (59)
miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells (2013) (58)
Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis. (1993) (58)
CNS Tumors in Neurofibromatosis. (2017) (58)
Advances in the treatment of neurofibromatosis-associated tumours (2013) (57)
HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1 (2015) (57)
Merlin isoform 2 in neurofibromatosis type 2–associated polyneuropathy (2013) (57)
Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation. (2014) (57)
The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the "open" conformation and suppresses cell growth and motility. (2001) (56)
Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner (2012) (56)
MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. (2013) (56)
Functional analysis of neurofibromatosis 2 (NF2) missense mutations. (2001) (55)
Differential Involvement of Protein 4.1 Family Members DAL-1 and NF2 in Intracranial and Intraspinal Ependymomas (2002) (55)
The Natural History and Treatment of Epilepsy in a Murine Model of Tuberous Sclerosis (2007) (55)
Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex (2005) (54)
Insights into Meningioangiomatosis with and without Meningioma: A Clinicopathologic and Genetic Series of 24 Cases with Review of the Literature (2005) (54)
Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras. (1996) (54)
ABCA1 influences neuroinflammation and neuronal death (2013) (53)
Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene (1996) (53)
Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. (1996) (53)
Neurofibromatosis Type 1: Piecing the Puzzle Together (1998) (53)
The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. (2015) (53)
The neurobiology of neurooncology (2006) (52)
Expression of the neurofibromatosis 2 (NF2) gene isoforms during rat embryonic development. (1995) (52)
Tumor suppressor Tsc1 is a new Hsp90 co‐chaperone that facilitates folding of kinase and non‐kinase clients (2017) (52)
NF1 mutation drives neuronal activity-dependent initiation of optic glioma (2021) (52)
Merlin: hanging tumor suppression on the Rac. (2001) (52)
Natural history of neurofibromatosis 1–associated optic nerve glioma in mice (2005) (51)
Loss of neurofibromatosis type I (NFI) gene expression in pheochromocytomas from patients without NFI (1994) (51)
let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-Like Receptor 7. (2019) (51)
Recent insights into neurofibromatosis type 1: clear genetic progress. (1998) (51)
Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. (1999) (51)
Recent progress toward understanding the molecular biology of von Recklinghausen neurofibromatosis (1992) (51)
Gliomas in patients with neurofibromatosis type 1 (2009) (50)
Midkine activation of CD8+ T cells establishes a neuron–immune–cancer axis responsible for low-grade glioma growth (2020) (50)
Pediatric gliomas as neurodevelopmental disorders (2015) (50)
Alterations in the rap1 signaling pathway are common in human gliomas (1997) (49)
Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays (2011) (49)
Oculodentodigital dysplasia syndrome associated with abnormal cerebral white matter. (1991) (49)
Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues (2015) (48)
NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. (2016) (48)
Neurodevelopmental disorders in children with neurofibromatosis type 1 (2017) (48)
Tuberous Sclerosis Complex: Pathogenesis, Diagnosis, Strategies, Therapies, and Future Research Directions (2004) (48)
Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma (2006) (47)
The mTOR signaling pathway as a treatment target for intracranial neoplasms. (2015) (47)
Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. (2008) (47)
Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein (2005) (46)
Molecular Insights into Neurofibromatosis 2 (1997) (46)
Gene Expression Profiling of NF-1-Associated and Sporadic Pilocytic Astrocytoma Identifies Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1) as an Underexpressed Candidate Biomarker in Aggressive Subtypes (2008) (46)
Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation (1993) (45)
Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1 (2013) (45)
Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. (2019) (45)
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft (2010) (45)
Optic Nerve Dysfunction in a Mouse Model of Neurofibromatosis-1 Optic Glioma (2009) (45)
Neurofibromatosis 2 and malignant mesothelioma. (2002) (44)
TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. (2007) (44)
Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. (2001) (42)
How Support of Early Career Researchers Can Reset Science in the Post-COVID19 World (2020) (42)
Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. (2017) (42)
Alterations of protein 4.1 family members in ependymomas: a study of 84 cases (2005) (42)
F11R Is a Novel Monocyte Prognostic Biomarker for Malignant Glioma (2013) (42)
The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. (2001) (41)
Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival (2017) (41)
Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology (2004) (41)
A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1 (2017) (41)
Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas (1997) (40)
The monolayer formation of Bergmann glial cells is regulated by Notch/RBP-J signaling. (2007) (40)
Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. (2005) (40)
Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma (2008) (39)
The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. (1995) (39)
Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines (2008) (39)
cDNA hybrid capture improves transcriptome analysis on low-input and archived samples. (2014) (39)
Evaluation of participant recruitment methods to a rare disease online registry (2014) (39)
CD44‐independent hepatocyte growth factor/c‐Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro (2004) (39)
Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. (2002) (37)
PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice (2011) (37)
Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma–induced retinal pathology (2017) (37)
Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. (2015) (36)
Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways (2015) (36)
Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. (2006) (35)
Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. (1995) (35)
Human iPSC-Derived Neurons and Cerebral Organoids Establish Differential Effects of Germline NF1 Gene Mutations (2020) (35)
Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. (1996) (35)
Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. (2012) (35)
Athymic mice reveal a requirement for T-cell–microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth (2018) (35)
Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma (2015) (35)
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 (2018) (35)
Aberrant G protein signaling in nervous system tumors. (2002) (34)
Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes (2011) (34)
Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia (1996) (34)
Fatty acid synthase as a novel target for meningioma therapy. (2010) (34)
Akt-Dependent Cell Size Regulation by the Adhesion Molecule on Glia Occurs Independently of Phosphatidylinositol 3-Kinase and Rheb Signaling (2005) (34)
A Conserved Circadian Function for the Neurofibromatosis 1 Gene (2018) (34)
Development of an international internet-based neurofibromatosis Type 1 patient registry. (2013) (34)
Neurofibromatosis type 1. (2018) (33)
Meningothelial Hyperplasia: A Detailed Clinicopathologic, Immunohistochemical and Genetic Study of 11 Cases (2005) (33)
Functional significance of S6K overexpression in meningioma progression (2004) (33)
The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. (2002) (33)
Developmental Delays in Children With Neurofibromatosis Type 1 (2012) (32)
RNA‐sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease (2015) (32)
Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival (2016) (32)
Antiangiogenic Agents for Nonmalignant Brain Tumors (2013) (32)
Overexpression of bax in human glioma cell lines. (1999) (32)
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma (2014) (32)
Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1 (2007) (31)
Mouse glioma gene expression profiling identifies novel human glioma‐associated genes (2002) (31)
BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. (2014) (31)
Characterization of early communicative behavior in mouse models of neurofibromatosis type 1 (2018) (31)
Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. (2013) (31)
Comparative Characterization of the Human and Mouse Third Ventricle Germinal Zones (2011) (31)
Hereditary retinal vasculopathy with cerebral white matter lesions. (1989) (31)
Tslc1 (nectin-like molecule-2) is essential for spermatozoa motility and male fertility. (2006) (30)
Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma (2008) (30)
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference (2020) (29)
Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression (2005) (29)
Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2 (2002) (29)
Reduced Activity of CD13/Aminopeptidase N (APN) in Aggressive Meningiomas Is Associated with Increased Levels of SPARC (2010) (29)
Glomus tumors in individuals with neurofibromatosis type 1. (2014) (29)
The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1) as a paradigm for translational research (2012) (29)
Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. (1994) (28)
Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial (2021) (28)
A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study. (2020) (28)
Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development. (1995) (28)
NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma (2014) (28)
Advances in Neurofibromatosis 2 (NF2): A Workshop Report (2000) (28)
Neurofibromatosis type 1. Beyond positional cloning. (1993) (28)
Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation (2016) (27)
Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. (2015) (27)
Spatiotemporal Differences in CXCL 12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1 (2007) (27)
Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction (2020) (27)
Ammonium acetate protocol for the preparation of plasmid DNA suitable for mammalian cell transfections. (1997) (27)
A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury* (2016) (27)
Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma (2010) (27)
Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo (2007) (27)
Height Assessments in Children With Neurofibromatosis Type 1 (2013) (27)
Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1 (2019) (26)
Novel BRAF Alteration in a Sporadic Pilocytic Astrocytoma (2012) (26)
Expression of the Tuberous Sclerosis 2 Gene Product, Tuberin, in Adult and Developing Nervous System Tissues (1996) (26)
Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions (2014) (26)
Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro (1995) (26)
Complicated hereditary spastic paraparesis with cerebral white matter lesions. (1990) (26)
Postoperative imaging surveillance in pediatric pilocytic astrocytomas. (2010) (26)
Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I (2016) (26)
Regulation of Mixed Lineage Kinase 3 is Required for Neurofibromatosis-2-Mediated Growth Suppression in Human Cancer (2010) (26)
Mouse models of human cancer consortium symposium on nervous system tumors. (2003) (26)
Role of the Rap1 GTPase in astrocyte growth regulation (2003) (25)
Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo (2002) (25)
Expression of the Tumor Suppressor Genes NF2, 4.1B, and TSLC1 in Canine Meningiomas (2009) (25)
HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. (2005) (25)
Mlh1 deficiency accelerates myeloid leukemogenesis in neurofibromatosis 1 (Nf1) heterozygous mice (2003) (25)
Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. (2008) (24)
Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell–Cell Interactions in Tumor Progression (2020) (24)
Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1. (2015) (24)
Optic nerve tortuosity in children with neurofibromatosis type 1 (2013) (24)
Neurofibromatosis Type 1 and Chronic Neurological Conditions in the United States: An Administrative Claims Analysis (2014) (24)
Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1 (2019) (23)
Activated K‐Ras, but Not H‐Ras or N‐Ras, Regulates Brain Neural Stem Cell Proliferation in a Raf/Rb‐Dependent Manner (2015) (23)
Molecular analysis of malignant triton tumors. (1999) (23)
Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age‐dependent manner (2017) (23)
Brain tumors in neurofibromatosis type 1 (2019) (23)
Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor (2006) (22)
Motivational Disturbances and Effects of L-dopa Administration in Neurofibromatosis-1 Model Mice (2013) (22)
Longitudinal Analysis of Developmental Delays in Children With Neurofibromatosis Type 1 (2013) (22)
Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays (2003) (22)
Mouse Models of Tuberous Sclerosis Complex (2004) (22)
Children with 5′-end NF1 gene mutations are more likely to have glioma (2017) (22)
Human stem cell modeling in neurofibromatosis type 1 (NF1) (2018) (22)
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors (2017) (22)
Molecular biology of duchenne and Becker's muscular dystrophy: Clinical applications (1989) (21)
Neurofibromatosis type 1 in childhood (1997) (21)
Microglia in the tumor microenvironment: taking their TOLL on glioma biology. (2015) (21)
Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1) (2021) (20)
Research updateMerlin: hanging tumor suppression on the Rac (2001) (20)
Patient-derived iPSC-cerebral organoid modeling of the 17q11.2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis (2021) (20)
A genotype–phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1 (2018) (20)
Defining Microglial States and Nomenclature: A Roadmap to 2030 (2022) (20)
Identification of transcriptional regulatory networks specific to pilocytic astrocytoma (2011) (20)
A Neuropsychological Perspective on Attention Problems in Neurofibromatosis Type 1 (2013) (20)
Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights (2018) (20)
New insights into the neurofibromatoses. (1994) (20)
Review Article : Neurofibromin in the Brain (2002) (20)
Juvenile Xanthogranuloma, Neurofibromatosis 1, and Juvenile Chronic Myeloid Leukemia (1996) (20)
Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study (2004) (20)
Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction (2016) (19)
3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. (2016) (19)
Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. (1999) (19)
Expression and Function of Somatostatin Receptors in Peripheral Nerve Sheath Tumors (2005) (19)
Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1 (2019) (19)
Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1 (2018) (19)
Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. (2008) (19)
The diagnostic evaluation and multidisciplinary management of NF1 and NF2 (1997) (18)
The ecology of brain tumors: lessons learned from neurofibromatosis-1 (2011) (18)
Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors. (2006) (18)
KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production (2018) (18)
Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation (2005) (18)
Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. (1996) (18)
Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. (2020) (18)
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies (2014) (18)
Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. (2009) (18)
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. (2022) (17)
On bone marrow-derived macrophages. (1982) (17)
Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration (2004) (16)
Conditional KIAA1549:BRAF mice reveal brain region‐ and cell type‐specific effects (2013) (16)
Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression (2004) (16)
Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging (2019) (16)
The impact of coexisting genetic mutations on murine optic glioma biology. (2015) (16)
Natural history of neurofibromatosis 1-associated optic nerve glioma in mice (2005) (16)
Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature. (2017) (16)
The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation (2017) (16)
Cancer stem cells and brain tumors: uprooting the bad seeds (2007) (16)
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. (1998) (16)
Validity of participant-reported diagnoses in an online patient registry: a report from the NF1 Patient Registry Initiative. (2015) (15)
Eliminating barriers to personalized medicine (2014) (15)
Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes (2018) (15)
Updated nomenclature for human and mouse neurofibromatosis type 1 genes (2017) (15)
Clearing the Fog surrounding Chemobrain (2019) (15)
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. (2010) (15)
Update from the 2013 international neurofibromatosis conference (2014) (15)
Learning disabilities in neurofibromatosis 1: sizing up the brain. (1999) (15)
Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative (2015) (15)
Piebaldism and neurofibromatosis type 1: horses of very different colors. (2004) (14)
Symptomatic hydrocephalus and reversible spinal cord compression in Listeria monocytogenes meningitis. Case report. (1989) (14)
Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report. (2007) (14)
A review of astrocytoma models (2000) (14)
Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. (2003) (14)
Transglutaminase 2 Expression Is Increased as a Function of Malignancy Grade and Negatively Regulates Cell Growth in Meningioma (2014) (13)
Parallels between tuberous sclerosis complex and neurofibromatosis 1: common threads in the same tapestry. (1998) (13)
Characterization and expression of H‐2I region gene products on bone marrow‐derived macrophages (1982) (13)
Nonoptic pathway tumors in children with neurofibromatosis type 1 (2020) (12)
Comments on neurofibromatosis 1 and optic pathway tumors. (2001) (12)
ABCG1 maintains high-grade glioma survival in vitro and in vivo (2016) (12)
CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice (2010) (12)
Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. (2017) (12)
Neurofibromatosis 2 in children presenting during the first decade of life (2019) (11)
Personality changes associated with thalamic infiltration (1990) (11)
The 43000 growth-associated protein functions as a negative growth regulator in glioma. (2003) (11)
Commentary: Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I (2019) (11)
Correction to: Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma (2020) (11)
Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia (2021) (10)
Nf2/Merlin Controls Spinal Cord Neural Progenitor Function in a Rac1/ErbB2-Dependent Manner (2014) (10)
Generation of a reporter mouse line expressing Akt and EGFP upon Cre‐mediated recombination (2008) (10)
Tumor suppressor genes as negative growth regulators in development and differentiation. (1995) (10)
Expression of the neurofibromatosis 1 (NF1) gene during growth arrest (1996) (10)
All in the family: Using inherited cancer syndromes to understand de‐regulated cell signaling in brain tumors (2007) (10)
Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1 (2022) (10)
Diethylstilbestrol effects and lymphomagenesis in Mlh1‐deficient mice (2005) (10)
Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma (2016) (9)
In–vitro–derived bone marrow macrophages (1984) (9)
Improving outcomes for neurofibromatosis 1–associated brain tumors (2015) (9)
Magnetic resonance imaging of ataxic hemiparesis localized to the corona radiata. (1989) (9)
The power of the few (2017) (9)
Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1 (2011) (9)
NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events (2019) (8)
Neurofibromatosis 1. (2002) (8)
Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study. (2010) (8)
The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: challenges, progress, and future prospects (2017) (8)
Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1 (2016) (8)
Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell. (1994) (8)
Global microRNA profiling identified miR‐10b‐5p as a regulator of neurofibromatosis 1 (NF1)‐glioma migration (2020) (8)
Visual function and optic pathway glioma: a critical response. (2013) (8)
Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1 (2019) (8)
KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth (2017) (8)
RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. (2021) (7)
Congenital nystagmus in a (46,XX/45,X) mosaic woman from a family with X-linked congenital nystagmus. (1991) (7)
NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC GLIOMA VISUAL OUTCOMES FOLLOWING CHEMOTHERAPY: AN INTERNATIONAL MULTI-CENTER RETROSPECTIVE ANALYSIS (2010) (7)
Anti-Angiogenic Agents for Non-Malignant Brain Tumors (2013) (7)
β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. (2018) (7)
Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1 (2019) (7)
Rethinking pediatric gliomas as developmental brain abnormalities. (2011) (7)
BRAF mutations may identify a clinically distinct subset of glioblastoma (2021) (7)
Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis (1990) (7)
RAS and beyond: the many faces of the neurofibromatosis type 1 protein (2022) (7)
Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. (2011) (7)
Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma (2018) (7)
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis (2017) (7)
A Pilot Study for Evaluation of Hypotonia in Children With Neurofibromatosis Type 1 (2015) (6)
Can the “female protective effect” liability threshold model explain sex differences in autism spectrum disorder? (2022) (6)
Genome‐wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma (2011) (6)
Short Communication NF1 Deletions in S-100 Protein-Positive and Negative Cells of Sporadic and Neurofibromatosis 1 (NF1)- Associated Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors (2001) (6)
Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas (2012) (6)
Contextual signaling in cancer. (2016) (6)
Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1 (2016) (6)
An alternative apnea test for the evaluation of brain death (1991) (6)
Reply: To PMID 24375753. (2014) (6)
Neurofibromatosis 1 - Mutant microglia exhibit sexually-dimorphic cyclic AMP-dependent purinergic defects (2020) (5)
Neurofibromatosis type 1 (Nf1)‐mutant mice exhibit increased sleep fragmentation (2019) (5)
T lymphocytes as dynamic regulators of glioma pathobiology. (2022) (5)
NF GEMMs already! The power and promise of mouse tumor models. (2014) (5)
In Vivo Functional Analysis of the Human NF2 Tumor Suppressor Gene in Drosophila (2014) (5)
Chromosome 11q23.3-qter deletion and Alexander disease. (1991) (5)
Imaging , Diagnosis , Prognosis Array-Based Comparative Genomic Hybridization Identifies CDK 4 and FOXM 1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor (2011) (5)
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1‐associated optic pathway gliomas in children (2020) (5)
Low‐grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis‐1 (2012) (5)
A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives glioblastoma progression (2022) (5)
Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. (2017) (5)
The Sociobiology of Brain Tumors. (2020) (5)
The taxonomy of brain cancer stem cells: what's in a name? (2014) (5)
Melanoma in individuals with neurofibromatosis type 1: a retrospective study. (2019) (4)
The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion (2017) (4)
Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. (2016) (4)
Defining the Research Landscape for Dermal Neurofibromas. (2016) (4)
Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders (2020) (4)
Sirolimus for progressive neuroﬁbromatosis type 1 – associated plexiform neuroﬁbromas: a Neuroﬁbromatosis Clinical Trials Consortium phase II study (2015) (4)
Gliosarcomas lack BRAFV600E mutation, but a subset exhibit β‐catenin nuclear localization (2016) (4)
SRF Is Required for Maintenance of Astrocytes in Non-Reactive State in the Mammalian Brain (2021) (4)
Separation of the immune response genes for LDH-B and MOPC-173. I. Description of an immune response defect in B10.BASR1. (1983) (4)
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. (1997) (4)
Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma. (2020) (4)
Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden (2020) (4)
Mice with GFAP‐targeted loss of neurofibromin demonstrate increased axonal MET expression with aging (2007) (4)
Reimagining Pilocytic Astrocytomas in the Context of Pediatric Low-Grade Gliomas. (2021) (4)
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children (2020) (4)
NF1-Associated Optic Glioma (2012) (4)
Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1 (2018) (3)
In-vitro-derived bone marrow macrophages. Expression of Ia antigens during macrophage differentiation. (1984) (3)
The Association Between Hypotonia and Brain Tumors in Children With Neurofibromatosis Type 1 (2013) (3)
Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature (2017) (3)
Major histocompatibility complex regulation of the immune response. (1985) (3)
Integrated MR imaging and proton nuclear magnetic resonance spectroscopy in a family with an X-linked spastic paraparesis. (1991) (3)
Lack ofNF1 expression in a sporadic schwannoma from a patient without neurofibromatosis (2005) (3)
Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes (2018) (3)
Pseudocervical cord syndrome: a deceptive flumazenil reversible manifestation of hepatic encephalopathy. (1996) (3)
Exploring the genetic basis for clinical variation in neurofibromatosis type 1 (2016) (3)
Neurocutaneous Disorders: Neurofibromatosis type 1 (2004) (3)
NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY (2018) (3)
Establishing priorities in neurofibromatosis research: A workshop summary (2001) (3)
Characterization and expression of H-21 region gene products on bone marrow-derived macrophages. (1982) (3)
Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation (2021) (2)
KIAA 1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NF κ B-Mediated CCL 2 Production (2019) (2)
which have GTPase-activating protein activity. produces two neurofibromin isoforms, both of Recklinghausen neurofibromatosis (NF1) gene A conserved alternative splice in the von (2012) (2)
Neurofibromatosis and other genetic syndromes. (2012) (2)
Teaching NeuroImages: T2 hyperintensities in neurofibromatosis type 1 (2013) (2)
Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. (2020) (2)
Whole Exome Sequencing Reveals the Order of GeneticChangesduringMalignantTransformation and Metastasis in a Single Patient with NF 1-plexiform Neuro fi broma (2015) (2)
the t(8;21) Fusion Protein Neurofibromatosis-1 Tumor Suppressor by Transcriptional Repression of the (2014) (2)
Modeling Human Brain Tumors in Mice (2009) (2)
Familial Lipomas Without Classic Neurofibromatosis-1 Caused by a Missense Germline NF1 Mutation (2021) (2)
Corrigendum to “The Learning Disabilities Network (LeaDNet): Using Neurofibromatosis Type 1 [NF1] as a Paradigm for Translational Research” (2013) (2)
produces two neurofibromin isoforms , both of Recklinghausen neurofibromatosis ( NF 1 ) gene A conserved alternative splice in the von (1992) (2)
Nf 2 / Merlin Controls Spinal Cord Neural Progenitor Function in a Rac 1 / ErbB 2-Dependent Manner (2014) (2)
Tumor suppressor gene regulation of cell growth (2007) (2)
Abstract 4847: Efficacy of different recruitment methods for a neurofibromatosis type 1 online registry. (2013) (2)
Reduced Brain Neurofibromatosis Type 1 (Nf1) Tumor Suppressor Gene Expression Confers Differential Sensitivity to Ionizing Radiation In Vivo (2013) (2)
THE DIAGNOSIS AND MANAGEMENT OF NEUROFIBROMATOSIS 1 (1998) (2)
Preclinical Development Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf 1-Deficient Astrocytes (2011) (1)
Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content (2021) (1)
Curr Top Dev Biol. 2011;94:283-308. (2011) (1)
Abstract GS2-02: Direct regulation of estrogen receptor-α (ER) transcriptional activity by NF1 (2018) (1)
Generation of human induced pluripotent stem cell-derived cerebral organoids for cellular and molecular characterization (2022) (1)
Limitations of magnetic resonance spectroscopy in patients with white matter disease (1994) (1)
Reply (2014) (1)
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1 (2019) (1)
NF 1 germline mutation differentially dictates optic glioma formation and growth in neuro fi bromatosis-1 (2016) (1)
TUMOR SUPPRESSOR TSC1 IS A NEW HSP90 COCHAPERONE THAT FACILITATES FOLDING OF KINASE AND NON‐KINASE CLIENTS: MP88‐13 (2018) (1)
De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging (2016) (1)
Expression of Ia Antigens and Ir Gene Function During Differentiation of Bone Marrow Derived Macrophage (1983) (1)
Reproducibility of cognitive endpoints in clinical trials (2019) (1)
ABCG 1 maintains high-grade glioma survival in vitro and in vivo (2018) (1)
A multidisciplinary approach in neurofibromatosis 1–Authors' reply (2015) (1)
Separation of the immune response genes for LDH-B and MOPC-173. II. Description of an immune response defect in B10.ASR7. (1984) (1)
Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial (2019) (1)
Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling (2022) (1)
Comparative Gene Expression Profile Analysis of Neurofibromatosis 1-associated and Sporadic Pilocytic Astrocytomas 1 (2002) (1)
NF 1-associated pilocytic astrocytoma Somatic neurofibromatosis type 1 ( NF 1 ) inactivation characterizes Material Supplemental (2013) (1)
The 43 , 000 Growth-associated Protein Functions as a Negative Growth Regulator in Glioma 1 (2003) (1)
MRI-guided laser interstitial thermal therapy for deep-seated gliomas in children with neurofibromatosis type 1: report of two cases (2022) (1)
Astrocytomas Neurofibromatosis 1-associated and Sporadic Pilocytic Comparative Gene Expression Profile Analysis of Updated Version (2002) (1)
Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2as3), B10.BAR4 (H-2h6), and B10.BASR1 (H-2as4) (2004) (1)
Omics and Prognostic Markers (2010) (1)
Proliferation Microglia Activation and Promotes Optic Glioma Neurofibromatosis-1 Heterozygous Microglia Drives-Kinase Signaling in 2 Increased c-Jun-NH Updated (2008) (1)
LGG-01. NF1 MUTATION DRIVES NEURONAL ACTIVITY-DEPENDENT OPTIC GLIOMA INITIATION (2021) (1)
Abstract 3448: Subtypes of medulloblastoma have distinct developmental origins (2011) (1)
Report of the National Neurofibromatosis Foundation (NNFF) Task Force on Treatment of Neurofibromatosis 1 (1997) (1)
Understanding a complicated Gal-1. (2019) (1)
Molecular genetics of optic glioma: lessons learned from neurofibromatosis-1 genetically engineered mice (2011) (1)
Astrocyte‐specific neurofibromatosis 1 gene deletion is insufficient for astrocytoma formation in mice (2008) (0)
LINC-08. Neuro-Oncology tumor board – one-year experience of international collaboration (2022) (0)
Insufficient for Astrocytoma Formation ) Is NF1 Neurofibromatosis 1 Gene ( Astrocyte-Specific Inactivation of the (2014) (0)
TMIC-06. IDENTITY AND GENE PROFILE OF TUMOR-ASSOCIATED MACROPHAGES IN GLIOBLASTOMA (2016) (0)
PDTM-07. DEFINING THE MECHANISMS UNDERLYING NF1 OPTIC GLIOMA PENETRANCE (2019) (0)
Clinical, Histological and Molecular Features of Gliomas in Adults with Neurofibromatosis Type 1. (2023) (0)
Negative Growth Regulator in Glioma The 43 , 000 Growth-associated Protein Functions as a Updated Version (2003) (0)
Molecular and Cellular Pathobiology Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP 1 toEnhanceGlioblastomaTumorigenicity (2014) (0)
Abstract 5521: Development of a web-based patient registry and DNA repository for pediatric cancer research in individuals with neurofibromatosis type 1 (2012) (0)
Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders (2021) (0)
LGG-50. Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling (2022) (0)
LAB-STEM CELLS (2012) (0)
Neurofibromin-Deficient Astrocytes Dependent Actin Cytoskeleton Dynamics and Proliferation in − Nucleophosmin Mediates Mammalian Target of Rapamycin (2007) (0)
Using the Neurofibromatosis Tumor Predisposition Syndromes to Understand Normal Nervous System Development (2014) (0)
Correction to: Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma (2020) (0)
Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma (2023) (0)
IMMU-23. ELIMINATING MONOCYTE CHEMOATTRACTION INVOKES COMPENSATORY NEUTROPHIL INFLUX AND PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA (2022) (0)
Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma (2019) (0)
Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1 (2015) (0)
Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future (2014) (0)
The novel compensatory reciprocal interplay between neutrophils and monocytes drives cancer progression (2022) (0)
LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (2021) (0)
The use of restriction endonucleases in the prenatal diagnosis of hemoglobinopathies. (1982) (0)
Genetic and serological separation of the immune response genes for lactate dehydrogenase b and mopc 173 (1983) (0)
CHAPTER 4 CNS myelination is dependent on astrocyte lipid metabolism (2013) (0)
DYNAMIC CHANGES IN LONG-TERM VISUAL OUTCOME AFTER TREATMENT OF CHILDREN WITH NF1 OPTIC PATHWAY GLIOMAS (2012) (0)
TMIC-04. CANCER STEM CELL GENETIC AND GENOMIC ALTERATIONS DIFFERENTIALLY DICTATE STROMAL CELL REGULATION OF LOW-GRADE GLIOMA GROWTH (2019) (0)
Abstract 2322: TheKIAA1549:BRAFfusion gene regulates mTOR signaling and gliomagenesis in a cell type- and brain region-specific manner. (2013) (0)
762 Overexpression of EGFRvIII Potentiates the Development and Aggressiveness of Astrocytomas in an Activated Ras Transgenic Mouse Astrocytoma Model (2001) (0)
Chapter 53 – Neurofibromatosis (2010) (0)
Erratum to: Optic nerve tortuosity in children with neurofibromatosis type 1 (2013) (0)
BRAF V 600 E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors (2013) (0)
Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic (2023) (0)
Neurofibromatosis Type 2: Natural History, Outcomes, and Treatment Patterns in a Large Contemporary Cohort (2016) (0)
Abstract 1530: The obligate role of microglia in tumorigenesis in a mouse model of neurofibromatosis-1 optic glioma (2012) (0)
Cancer neuroscience: State of the field, emerging directions (2023) (0)
GENO-06A PAN-GLIOMA CHARACTERIZATION OF GENOMIC, EPIGENOMIC AND TRANSCRIPTOMIC ACTIVITIES REVEALS NOVEL RELATIONSHIPS BETWEEN HISTOLOGICAL SUBTYPES AND MOLECULAR SIGNATURES (2015) (0)
Glial Tumors in Neurofibromatosis and Tuberous Sclerosis Complex (2012) (0)
Restriction endonucleases. (1983) (0)
MUTANT EGFR SUPPRESSION OF MICRORNA-9 INDUCES FOXP1 TO ENHANCE GLIOBLASTOMA TUMORIGENICITY (2014) (0)
Racial / Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neuro fi bromatosis Type 1 (2015) (0)
Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’ (2019) (0)
LB1084 Developing uniform datasets for tissue based studies of cutaneous neurofibromas (2019) (0)
Human induced pluripotent stem cell modeling of neurofibromatosis type 1 (2022) (0)
643: Transglutaminase 2, a potential biomarker and therapeutic target for meningioma by microarray analysis (2014) (0)
Chapter 79 – Neurofibromatoses (2015) (0)
Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas (2012) (0)
EXCELLENT LONG-TERM VISUAL PROGNOSIS FOLLOWING CHEMOTHERAPY FOR NF1 ASSOCIATED OPTIC PATHWAYS GLIOMAS WITH NORMAL BASELINE VISUAL ACUITY (2012) (0)
A Recombinatorial Event Separating the Immune Response Genes for LDH-B and MOPC-173: Implications for a New Model of I Region Gene Organization (1983) (0)
TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1 (2019) (0)
Predictors of patient return to a tertiary neurofibromatosis subspecialty clinic. (2022) (0)
THREE YEAR VISUAL OUTCOMES AFTER CHEMOTHERAPY FOR NF1 OPTIC PATHWAY GLIOMAS IN CHILDREN (2012) (0)
Rapid Purification of Reporter Group-Tagged Inositol Hexakisphos-phate on Ion-Exchange Membrane (0)
PATH-15. MICROGLIA/MACROPHAGES ARE THE MAJOR TUMOR-ASSOCIATED IMMUNE CELLS IN PILOCYTIC ASTROCYTOMA (2018) (0)
Abstract 358: Nf1 inactivation in NG2-cells is not sufficient for murine optic glioma formation. (2013) (0)
Abstract 1074: Tumor-associated microglia secrete paracrine factors that promote Nf1-deficient optic glial cell growth (2014) (0)
Caddyshack therapeutics: overcoming glioblastoma adaptation. (2017) (0)
Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial (2021) (0)
Children with supratentorial midline pilocytic astrocytomas exhibit multiple progressions and acquisition of neurologic deficits over time (2021) (0)
The effect of tumor formation and treatment on retinal dysfunction in mouse models of Neurofibromatosis type 1 (NF1)-associated optic glioma. (2015) (0)
EPID-18THE ASSOCIATION BETWEEN ALLERGIC CONDITIONS AND PEDIATRIC BRAIN TUMORS IN NEUROFIBROMATOSIS TYPE 1 (2015) (0)
Pediatric Low-Grade Glioma: The Role of Neurofi bromatosis-1 in Guiding Therapy (2012) (0)
Using Genetically Engineered Mouse Models to Understand Low-Grade Glioma Development and Growth in Children (2012) (0)
Predictive Modeling for Clinical Features Associated With Neurofibromatosis Type 1 (2021) (0)
Immune response defect in an intra-I-region recombinant mouse strain is localized to the level of the antigen-presenting cell (1984) (0)
NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma (2022) (0)
low-grade glioma formation. (2017) (0)
Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas (2009) (0)
neurofibromatosis type 1 Eliminating barriers to personalized medicine: Learning from (2014) (0)
Abstract 1295: The association between asthma and pediatric brain tumors in neurofibromatosis type 1 (2014) (0)
LGG-54. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia (2022) (0)
Title The path forward : 2015 International Children ' s Tumor Foundation conference on neurofibromatosis type 1 , type 2 , and schwannomatosis Permalink (2017) (0)
TAMI-69. NF1 MUTATION DRIVES NEURONAL ACTIVITY-DEPENDENT OPTIC GLIOMA INITIATION (2021) (0)
Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative (2014) (0)
STMC-01. OLIGODENDROCYTE PRECURSOR CELL HYPERCELLULARITY IN A MOUSE MODEL OF NEUROFIBROMATOSIS TYPE (NF1) RESEMBLES PRENEOPLASTIC LESIONS (2017) (0)
Abstract 2498: Differential rapamycin sensitivity distinguishes two distinct populations of tumor cells in murine glioma (2012) (0)
Mouse Models of Neurofibromatosis 1 and 2 1 (2002) (0)
GLIA/ASTROCYTES | Glial-Mediated Mechanisms of Epileptogenesis in Tuberous Sclerosis (2009) (0)
LGG-01. Children with Supratentorial Midline Pilocytic Astrocytomas Exhibit Multiple Progressions and Acquisition of Neurologic Deficits over Time (2022) (0)
Abstract P1-08-01: Regulation of estrogen receptor-α by NF1 (2017) (0)
Characterization of bone marrow derived macrophage as Ia-bearing accessory cells. (1982) (0)
Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes (2018) (0)
NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY (2020) (0)
Physiatry and Care of Patients With Neurofibromatosis-Reply (1997) (0)
Molecular Oncology: Neurofibromatosis type I (2013) (0)
TMIC-10. AN IL-1β/IL-1R PRO-TUMORIGENIC SIGNALING LOOP IN GLIOBLASTOMA (2016) (0)
Recent Insights Into Neurofibromatosis Type 1 (2016) (0)
Abstract 4186: Development of a novel, genetically faithful model of pediatric glioblastoma (2010) (0)
A multi-institutional study of brainstem gliomas in childrenwith neurofibromatosis type 1 (0)
Neurofibromatosis 1 and 2 (2006) (0)
Neurofibromatosis-1 Gene Mutational Profiles Differ Between Syndromic Disease and Sporadic Cancers (2022) (0)
Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1. (2022) (0)
FOXP 1 to Enhance Glioblastoma Tumorigenicity Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates (2014) (0)
Erratum to “KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production” [Neoplasia, Volume: 21, Issue:1, (2019) 52–60] (2020) (0)
Neurons as stromal drivers of nervous system cancer formation and progression. (2023) (0)
SEPARATION OF THE IMMUNE RESPONSE GENES FOR LDH‐B AND MOPC‐173: III. EVIDENCE THAT THE FAILURE OF B10.BASR1 TO RESPOND TO LDH‐B IS DUE TO AN ANTIGEN‐PRESENTING CELL DEFECT (1985) (0)
CHAPTER 5 GFAP-SCAP mutant mice are impaired in LTP and contextual fear memory (2013) (0)
Peripheral Nervous System Tumors (2004) (0)
Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1 (2022) (0)
Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. (2017) (0)
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 (2018) (0)
IS VISUAL ACUITY DETERIORATION THE ONLY INDICATION TO INITIATE THERAPY FOR NF1 ASSOCIATED OPTIC PATHWAY GLIOMAS (2012) (0)
Expression in a Transgenic Mouse Glioma Model Loss or Mutant Epidermal Growth Factor Receptor High-Grade Glioma Formation Results from Postnatal Pten (2006) (0)

This paper list is powered by the following services:

Other Resources About David H. Gutmann

What Schools Are Affiliated With David H. Gutmann?

David H. Gutmann is affiliated with the following schools:

David H. Gutmann's Academic­Influence.com Rankings